Compugen Ltd. (NASDAQ:CGEN) Q2 2023 Earnings Call Transcript

Unidentified Analyst: It does. Thank you all. Appreciate it.

Operator: The next question is from Tony Butler of EF Hutton. Please go ahead.

Tony Butler: Good morning. I would like to go back to this notion of PVRL2 dominance, at least over PVR, which seems to be a recurring theme in some of the cohorts in which you’re attempting to move forward with the triple combination, and in particular, of course, 701. And that’s back to ASCO, where you had some really good data in endometrial cancer. The cut off, I recall, was in April, the 2 responses and then 2 patients who had stable disease. And I wondered if there was any additional information on follow-up, that is, were patients actually able to show an additional reduction in tumor size of those responses and/or of those patients who had stable disease? Thank you.

Anat Cohen-Dayag: Eran, would you like to address the PVRL2 portion?

Eran Ophir: So the PVRL2 portion, I think that it’s not only PVRL2, I mean, in general, it’s the PVRIG pathway dominance. PVRL2, obviously, is an important part of it. And this is again a measure that we looked at in both endometrial, which have a dominance and also another indication, as mentioned before.

Tony Butler: Fine.

Anat Cohen-Dayag: Henry, anything more to add?

Henry Adewoye: Nothing more to add to what Eran has mentioned.

Tony Butler: But anything more on the patients for additional follow-up that were presented at that time.

Anat Cohen-Dayag: So we are going to present follow-up data on these patients, remember that when we shared the data in December at ESMA in December 2022. We had patients that were still on study treatment responsive patients, some of them had durability of more than 9 months. We are going to present data by year-end follow-up data for these patients. So I guess that you’ll have answers to some of your questions then.

Tony Butler: I just want to be sure that’ll include the endometrial patients. That’s what I’m focusing on?

Anat Cohen-Dayag: Oh, no, it will relate to the ovarian – sorry, I misheard your question, it will relate to the ovarian. No, we didn’t plan yet to have any follow-up on the ovarian cancer – on the endometrial cancer patients.

Tony Butler: Okay. Thank you.

Operator: This concludes the Q&A session and Compugen’s investor conference call. Thank you for your participation. You may go ahead and disconnect.